Tag Archives: drug development

International Rare Disease Day: Join the Movement

Nicole Boice

By Nicole Boice, President and Founder, RARE Project Being diagnosed with any illness can be overwhelming. Imagine what it’s like, though, to be diagnosed with a disease that you’ve never heard of – maybe even one that your doctor has never seen before. Millions of people start this diagnostic odyssey on their own, with little or no support, no real direction, with feelings of isolation and fear. That’s exactly the situation in which millions of Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

“Alz” Well That Ends Well: The Beta-Amyloid Debate in Alzheimer’s Research

alzheimers

Researchers and clinicians alike believe there is substantial evidence to support the hypothesis that Alzheimer’s disease (AD) may be caused by deposition of amyloid beta-peptide (Abeta) in plaques in brain tissue. But drugs targeted towards the beta-amyloid have met with significant setbacks challenging whether the target is, in fact, real. With several late stage drugs targeting beta-amyloid poised for market entry, a panel of opinion leaders in the treatment of Alzheimer’s and scientific industry specialists Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

The Real Reason Why Salk Refused to Patent the Polio Vaccine

Vaccine

Editor’s Note: Despite the progress in polio and other diseases made possible by vaccines, today we are witnessing a resurgence of vaccine-preventable illnesses as nervous parents skip their children’s shots. Watch the PBS documentary Vaccines—Calling the Shots to find learn more.  BIO is also a leading voice on the patent-ability of biotech inventions and other IP matters. To get the most recent updates on IP in the biotech world, please sign up for BIO’s free bi-monthly IP Newsletter. Read More >

Patently BIOtech  |  24 Comments  |  Email This Post
Tags: , , , , , , ,

IBM’s Watson: From Jeopardy! to Drug Research

IBM's Watson Computer System Plays Jeopardy! in a Practice Round

Bits of technology from I.B.M.’s Watson are beginning to be used in actual products available to corporate clients. The cloud-based Strategic Intellectual Property Insight Platform “uses data mining, natural-language processing and analytics to pore through millions of patent filings and biomedical journals to look for chemical compounds used in drug discovery.” As a byproduct of this project, I.B.M. is contributing their research to the searchable NIH chemical database, which will ease access to information previously Read More >

Health  |  1 Comment  |  Email This Post
Tags: , ,

Where’s the Deal?

2011-drug-deals-thumb

With only two weeks to go in 2011 it is looking like a five year low for deals. The chart below shows therapeutic deals dropping every year since 2007. We use the Windhover/Elsevier Strategic Transaction Database as our starting point for deal analytics. We analyze each deal to determine if the deal is for a drug asset, removing generic/OTC deals, manufacturing/service deals, device/diagnostics/tools deals, and tech transfer deals. What remains are deals for biotech company Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,